5 results

Posted on 26.07.2017
The role of medtech in fighting hepatitis
International efforts to tackle the hepatitis pandemic have reached new heights, especially in the past year since the 69th World Health Assembly (WHA) endorsed the Global Health Sector Strategy (GHSS) on viral hepatitis 2016–2021. It is estimated that some 325 million people worldwide are living with chronic hepatitis B virus (HBV) or hepatitis C virus […]

Posted on 29.07.2014
Superbugs: “The physician community needs to get its act together”
The WHO has been raising the ‘threat level’ on this issue progressively each year for the last decade, with individual disease reports highlighting the emerging threat of antimicrobial resistance (AMR). This year’s report however highlights this pandemic like never before, demonstrating it’s global nature and its profound impact on health and economics. I’m a cardiologist and the report speaks to me – actually it screams out loud: “We need to get our act together”.

Posted on 24.03.2014
HIV 101: Tuberculosis and HIV, a Killer Combination
Today, March 24, is World TB Day. We’re examining the link between HIV and tuberculosis (TB) infections and how, by fighting these diseases together, we can create a generation free of HIV and TB!

5 WHO insights into conquering the medtech mismatch
One central theme revolved around the Second World Health Organisation’s Global Forum on Medical Devices – the WHO recognises medical devices as an investment and not a cost. However, there is a mismatch between innovation of medical devices and public health needs. 677 participants from 108 countries took their pick from 28 workshops and 4 plenary sessions. Held on November 22-24th in Geneva, the event enabled academia, international organisations, industry and NGOs to gain insight from 159 presentations, 144 posters (one of which was presented by EDMA on Lab Tests Online), and 8 films.

Curbing the burden of disease through rapid diagnostics tools
Infectious diseases remain a source of concern in the EU due to the emergence of new resistance to anti-infective drugs. The EU is supporting the deployment of innovative solutions in low resource settings in the world with the aim to help the local populations avoid the emergence of new resistance that can spread across borders.